IL2 and neoplasm: These first-generation CARs were able to specifically recognize and kill tumor targets as well as produce interleukin-2 (IL-2) in vitro [3]; however, they are unsuitable for clinical application due to their suboptimal persistence and anti-tumor activity [4].